Medinet Co
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 13.1m | 7.7m | - | 6.0m | 5.3m | 4.9m | 5.1m |
| % growth | - | (41 %) | - | - | (13 %) | (7 %) | 4 % |
| EBITDA | (11.4m) | - | - | (6.0m) | (7.4m) | (9.4m) | (10.1m) |
| % EBITDA margin | (87 %) | - | - | (100 %) | (142 %) | (192 %) | (198 %) |
| Profit | (20.0m) | (23.5m) | - | (6.5m) | (6.5m) | (9.7m) | (11.1m) |
| % profit margin | (153 %) | (305 %) | - | (108 %) | (123 %) | (198 %) | (217 %) |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | N/A | IPO |
JPY512m | Post IPO Equity | ||
| Total Funding | - | ||
Recent News about Medinet Co
EditMEDINET Inc. is a prominent Contract Development and Manufacturing Organization (CDMO) specializing in regenerative medicine and cell therapy. The company operates in Japan and serves a diverse range of clients, including pharmaceutical companies, biotech firms, and research institutions. MEDINET provides end-to-end solutions encompassing pre-clinical research, development, manufacturing, and commercial launch of cell-based therapies. The company's advanced Cell Processing Facility (CPF) in Shinagawa is equipped to meet stringent regulatory standards in Japan, the US, and Europe. MEDINET generates revenue through service contracts with its clients, offering expertise and state-of-the-art facilities to support the entire value chain of regenerative medicine.
Keywords: regenerative medicine, cell therapy, CDMO, cell processing, pre-clinical research, development, manufacturing, commercial launch, Shinagawa CPF, regulatory compliance.
